Stockscreener 앱 받기
6.31
9.17%
0.53
시간 외 거래:
6.31
전일 마감가:
$5.78
열려 있는:
$5.8
하루 거래량:
4.72M
Relative Volume:
5.04
시가총액:
$291.70M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-1.9238
EPS:
-3.28
순현금흐름:
$-78.56M
1주 성능:
-2.92%
1개월 성능:
-24.97%
6개월 성능:
-72.09%
1년 성능:
-66.88%
1일 변동 폭
$5.74
$6.37
1주일 범위
$5.58
$6.77
52주 변동 폭
$5.58
$36.25
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
FDMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
6.31 | 291.70M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Benzinga
Bank of America Has Lowered Expectations for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price - MarketBeat
Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Increases By 8.8% - MarketBeat
4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com India
4DMT Announces Landmark Publication of 4D-150 Preclinical - GlobeNewswire
4D Molecular's R100 Vector Shows 10X Potency Breakthrough in Landmark Eye Disease Study - StockTitan
4D Molecular Therapeutics stock hits 52-week low at $6.69 By Investing.com - Investing.com Canada
4D Molecular Therapeutics issues pre-funded warrant to RA Capital - Investing.com
4D Molecular Therapeutics issues pre-funded warrant to RA Capital By Investing.com - Investing.com Canada
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
84,322 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by Walleye Capital LLC - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - The Eastern Progress Online
BlackRock, Inc. Expands Stake in 4D Molecular Therapeutics Inc - GuruFocus.com
4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal phase - Investing.com India
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Redmile Group LLC - MarketBeat
4D Molecular Therapeutics stock hits 52-week low at $7.32 By Investing.com - Investing.com South Africa
4D Molecular Therapeutics stock hits 52-week low at $7.32 - Investing.com India
Healthcare of Ontario Pension Plan Trust Fund Sells 247,000 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Braidwell LP Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now - Insider Monkey
4D Molecular Therapeutics (NASDAQ:FDMT) Now Covered by Morgan Stanley - Defense World
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth - Simply Wall St
Morgan Stanley sees competitive challenges ahead for 4D Molecular stock By Investing.com - Investing.com Canada
4D Molecular initiated by Morgan Stanley at underweight - MSN
FY2024 Earnings Forecast for FDMT Issued By Leerink Partnrs - MarketBeat
HC Wainwright Has Negative Outlook for FDMT FY2024 Earnings - MarketBeat
4D Molecular Therapeutics’ Positive Q3 and Strategic Advances - TipRanks
RA Capital Management, L.P. Increases Stake in 4D Molecular Ther - GuruFocus.com
Janus Henderson Group PLC's Strategic Adjustment in 4D Molecular Therapeutics Inc Holdings - GuruFocus.com
Analyst Expectations For 4D Molecular Therapeutics's Future - Benzinga
Deep Track Capital, LP Increases Stake in 4D Molecular Therapeutics Inc - GuruFocus.com
4D Molecular Sets Major Conference Schedule: Jefferies, Evercore & OIS XIV Appearances | FDMT Stock News - StockTitan
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Inc Reports Q3 2024 EPS of $(0.79) and Revenue of $3,000 - GuruFocus.com
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Reports Positive AMD Trial Data, $551M Cash Position Funds Operations to 2027 | FDMT Stock News - StockTitan
4D Molecular Therapeutics stock hits 52-week low at $7.9 By Investing.com - Investing.com Australia
4D Molecular Therapeutics stock hits 52-week low at $7.9 - Investing.com India
4D Molecular Therapeutics Inc. (FDMT) Quarterly 10-Q Report - Quartz
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $47.14 Consensus PT from Analysts - MarketBeat
BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace
X-Linked Retinitis Pigmentosa Clinical Trials 2024: FDA - openPR
Goldman Sachs Group Inc's Strategic Reduction in 4D Molecular Th - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):